Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOPEVAC-Las Vaccine Candidate Against Lassa Fever in Healthy Volunteers
NCT07833436Phase 1Recruiting
- Sponsor
- Institut Pasteur
- Start
- Sep 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MOPEVAC-Las in Lassa fever (3 arms), sponsored by Institut Pasteur. Primary endpoint: Rate of solicited and unsolicited Adverse Events. Started Sep 2026; status: recruiting.
02
Drugs
MOPEVAC-Las
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT07833436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07833436.